Breast Clinical Trials

2,739 recruitingLast updated: June 17, 2026

There are 2,739 actively recruiting breast clinical trials across 87 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Breast Trials at a Glance

2,739 actively recruiting trials for breast are listed on ClinicalTrialsFinder across 6 cities in 87 countries. The largest study group is Not Applicable with 872 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running breast studies include Fudan University, Memorial Sloan Kettering Cancer Center, and Mayo Clinic.

Treatments under study

About Breast Clinical Trials

Looking for clinical trials for Breast? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Breast trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Breast clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,739 trials

Recruiting
Phase 4

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Breast Neoplasm Female
University of Wisconsin, Madison50 enrolled2 locationsNCT03096418
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 2

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

Advanced Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.36 enrolled1 locationNCT07597629
Recruiting
Phase 2

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Advanced Breast Cancer
AstraZeneca24 enrolled6 locationsNCT07427394
Recruiting
Not Applicable

Utility of a Mobile Application for Young Women With Breast Cancer

Breast CancerCancer Distress
Wake Forest University Health Sciences120 enrolled1 locationNCT07009093
Recruiting
Phase 3

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

HR+/HER2- Breast Cancer
BeOne Medicines1,056 enrolled13 locationsNCT07492641
Recruiting
Phase 2

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Breast Carcinoma
Mayo Clinic60 enrolled5 locationsNCT05557877
Recruiting
Phase 2

Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors

Estrogen Receptor-Positive Breast Carcinoma
Mayo Clinic80 enrolled23 locationsNCT06028022
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 2

Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.

TNBC - Triple-Negative Breast CancerBrain Metastasases
Fudan University58 enrolled1 locationNCT07638852
Recruiting
Phase 3

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)1,978 enrolled19 locationsNCT07391774
Recruiting
Not Applicable

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Wake Forest University Health Sciences120 enrolled2 locationsNCT07474090
Recruiting
Phase 1Phase 2

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Breast Cancer
Genentech, Inc.285 enrolled45 locationsNCT07100106
Recruiting
Phase 2

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Breast Cancer
Hoffmann-La Roche80 enrolled45 locationsNCT07405801
Recruiting
Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled183 locationsNCT07060807
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled541 locationsNCT06058377
Recruiting
Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Breast CancerPancreatic CancerOvarian Cancer+2 more
National Cancer Institute (NCI)124 enrolled1 locationNCT02830724
Recruiting
Early Phase 1

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer

Breast Carcinoma
Mayo Clinic55 enrolled1 locationNCT05704283
Recruiting
Phase 1

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

HER2-positive Breast Cancer
University of Alabama at Birmingham25 enrolled1 locationNCT04332588